Method for detecting biological activity of insulin or analogue thereof and kit
By using the luciferase reporter cell line with STAT5b response element sequence in insulin activity detection, the problems of high detection cost and complex operation in the prior art are solved, and efficient and accurate insulin activity detection is achieved, which is suitable for industrial production.
Patent Information
- Application Number
- PCT/CN2024/093792
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-29
- Filing Date
- 2024-05-17
- Publication Date
- 2024-12-05
AI Technical Summary
The existing insulin activity detection methods are costly, complex in operation, and cumbersome in detection steps, which limit their widespread use in practical applications.
A cell line containing a luciferase reporter gene of STAT5b response element sequence was designed to evaluate the biological activity of insulin or its analogues by detecting luciferase activity, simplifying the detection steps and reducing costs.
It achieves higher detection accuracy, sensitivity and simplicity of operation, expands the detection window value, reduces the detection cost, and is suitable for quality control analysis in industrial production.
Smart Images

Figure PCTCN2024093792-FTAPPB-I100001 
Figure PCTCN2024093792-FTAPPB-I100002 
Figure PCTCN2024093792-FTAPPB-I100003
Abstract
Description
Method and kit for detecting biological activity of insulin or its analogs
[0001] This application claims priority to Chinese Patent Application No. 202310620396.9 filed with the State Intellectual Property Office on May 29, 2023; the entire contents of which are incorporated herein by reference. Technical Field
[0002] The present invention relates to the field of genetic engineering, and more particularly to methods and kits for detecting the biological activity of insulin or its analogs. More particularly, it relates to isolated nucleic acid molecules, expression vectors, recombinant cells, methods for detecting the activity of insulin or its analogs, kits, and uses thereof. Background Art
[0003] Insulin is an important hormone that plays multiple physiological functions in the human body, including regulating blood sugar and promoting glucose uptake and utilization. Testing insulin activity can help doctors or researchers better understand the levels and functional status of insulin in a person's body. Testing insulin activity can be used to diagnose and monitor diabetes. Diabetic patients often experience hyperglycemia caused by insufficient insulin secretion, abnormal insulin receptors, and other issues. Testing insulin activity can help doctors determine the type of diabetes and guide the development and adjustment of treatment plans. Secondly, for drug development and clinical trials, testing the activity of insulin or its analogs can help evaluate the impact and efficacy of new drugs on insulin, thereby guiding research and development directions and the selection of drug treatment plans.
[0004] The insulin signaling pathway is closely linked to type 2 diabetes. Insulin first binds to the insulin receptor (IR) on the cell membrane. The IR is a transmembrane glycoprotein with tyrosine kinase activity. After insulin binds to the IR, its tyrosine kinase activity is activated, and the insulin receptor substrate (IRS) is phosphorylated, triggering a series of physiological reactions within the cell. Currently, multiple substrate molecules of the IR have been identified, and signal transducer and activator of transcription 5b (STAT5b) is one of these IRSs. STAT5b interacts with tyrosine 960 of the IRβ subunit through its SH2 sequence and can be phosphorylated by the purified insulin receptor tyrosine kinase active domain. Insulin can stimulate the tyrosine phosphorylation of endogenous STAT5b in cells with high IR expression.
[0005] Currently, commercial kits such as HTRF (homogeneous time-resolved fluorescence) and AlphaElisa are commonly used to detect insulin activity. These assays measure insulin IRβ receptor phosphorylation levels to characterize insulin's cellular bioactivity. On the one hand, commercial kits such as HTRF and AlphaElisa are expensive and require high testing costs. On the other hand, these techniques are complex to operate, typically requiring the addition of insulin to cells for co-incubation, followed by the addition of lysis buffer for lysis, followed by the addition of the corresponding phosphorylation antibody solution for incubation, and finally, testing. Typically, the sample volume for each step in these kits must be controlled to 4-8 μl, requiring a high level of analytical skill. Increasing the sample volume also requires increasing the volume of reagents in the kit to meet the test method requirements, significantly increasing testing costs. This is detrimental to companies' quality control and testing costs, resulting in relatively low practicality.
[0006] Therefore, there is an urgent need in this field to develop a method for detecting insulin activity that is efficient, accurate, highly sensitive, has a wide window value, is easier to operate, and has lower detection costs.
[0007] Summary of the Invention
[0008] This application is based on the inventor's discovery and understanding of the following facts and problems:
[0009] For the currently available insulin activity detection method, although it can be detected by commercial test kits such as HTRF (homogeneous time-resolved fluorescence) and AlphaElisa, due to its high cost, the detection steps are cumbersome, which seriously limits the transformation application of its detection method. Therefore, the inventors designed a new STAT5b response element sequence to construct a cell strain containing a luciferase reporter gene, and detected the activity of insulin or its analog under the condition of the presence of luciferase. The detection method of the present invention overcomes the drawbacks of high cost and low practicality of commercial test kits, and has the advantages of larger detection window value, higher accuracy, better precision, smaller variation, easier operation, and lower detection cost in the detection method.
[0010] In its first aspect, the present invention provides an isolated nucleic acid molecule. According to an embodiment of the present invention, the isolated nucleic acid molecule comprises a first nucleic acid segment encoding insulin receptor B; a second nucleic acid segment encoding a STAT5b response element; and a third nucleic acid segment encoding a reporter gene; the STAT5b response element comprising a nucleic acid sequence as set forth in any one of SEQ ID NOs: 1 to 3, wherein the first nucleic acid segment, the second nucleic acid segment, and the second and third nucleic acid segments are linked or unlinked. Preferably, the second nucleic acid segment is linked to the third nucleic acid segment.
[0011] The first fragment - insulin receptor (IRB): is a transmembrane glycoprotein with tyrosine kinase activity. After insulin binds to IR, its tyrosine kinase activity is activated, and the insulin receptor substrate (IRS) is phosphorylated and activated, thereby causing a series of physiological reactions in the cell. The need to overexpress the target receptor in the constructed cells is the basis of the invention for detecting the IRB phosphorylation biological activity of insulin and its analogs. The first fragment of the present invention is not connected to the second and third fragments. According to the principles of molecular biology, the first fragment can be independent of the second and third fragments, or it can be connected to the second and third fragments for transfection and construction.
[0012] The second segment - STAT5b response element: After the insulin receptor B is activated, the signal is transduced to the STAT5b response element and the transcription activator 5b (STAT5b), which is one of the IRS. That is, after the insulin receptor B is activated, the STAT5b response element will be activated and mediate the increase in the level of STAT5b.
[0013] The third segment—the reporter gene—activates STAT5b via insulin receptor tyrosine kinase (IRTK), binding to target gene regulatory sequences within the nucleus containing the STAT5b response element, thereby activating target gene transcription and expression. Specifically, the activated second segment, the STAT5b response element, regulates reporter gene transcription and luciferase expression. Luminescence is measured after addition of luciferase substrate, and the luciferase level is translated to reflect STAT5b levels, ultimately reflecting insulin receptor B phosphorylation. This reporter gene (the third segment) must be directly linked to and responsive to STAT5b levels. Therefore, the second and third segments must be linked so that activation of the STAT5b response element activates the constructed cellular reporter gene, acting as a further signal. This leads to transcription and expression of luciferase, ultimately reflecting insulin receptor B phosphorylation levels and, therefore, the IRB biological activity of insulin and its analogs.
[0014] According to an embodiment of the present invention, after the insulin receptor B in the isolated nucleic acid molecule binds to insulin, it activates the tyrosine kinase activity of the insulin receptor B and phosphorylates and activates signal transducer and activator of transcription 5b (STAT5b), thereby causing transcription and expression of a reporter gene. By detecting the expression level of the reporter gene, the activity of insulin or its analogue is determined. The detection method of the present invention has higher sensitivity, stronger specificity, better repeatability, and higher accuracy, and is more suitable as a quality control analysis method in industrial production.
[0015] According to an embodiment of the present invention, the isolated nucleic acid molecule may further include at least one of the following additional technical features:
[0016] According to an embodiment of the present invention, the STAT5b response element comprises the nucleic acid sequence shown in SEQ ID NO:3.
[0017] According to an embodiment of the present invention, the reporter gene includes at least one of a Luciferase gene, a CAT gene, a YFP gene, or a GFP gene. According to an embodiment of the present invention, the aforementioned reporter gene is selected because of its advantages of high detection sensitivity, ease of operation, wide applicability, and visual observation.
[0018] According to an embodiment of the present invention, the reporter gene is a Lucifererase gene.
[0019] According to an embodiment of the present invention, the insulin receptor protein B comprises the amino acid sequence shown in SEQ ID NO: 4,
[0020] According to an embodiment of the present invention, the reporter gene comprises the amino acid sequence shown in SEQ ID NO: 5,
[0021] According to an embodiment of the present invention, the first nucleic acid fragment comprises the nucleotide sequence shown in SEQ ID NO: 6,
[0022] According to an embodiment of the present invention, the third nucleic acid fragment comprises the nucleotide sequence shown in SEQ ID NO: 7,
[0023] It should be noted that the reporter gene can be replaced based on experimental requirements, or can be obtained by purchasing a plasmid containing the reporter gene.
[0024] In a second aspect, the present invention provides an expression vector. According to embodiments of the present invention, the expression vector carries at least any one of the nucleic acid fragments or nucleic acid molecules described in the first aspect of the present invention. According to embodiments of the present invention, the expression vector can efficiently express the nucleic acid molecule in suitable recipient cells, and the nucleic acid molecule has enhanced specificity.
[0025] According to an embodiment of the present invention, the above-mentioned expression vector may further include at least one of the following additional technical features:
[0026] According to an embodiment of the present invention, the expression vector is a non-pathogenic viral vector.
[0027] According to an embodiment of the present invention, the non-pathogenic virus is selected from at least one of a retrovirus, a lentivirus and an adenovirus-associated virus.
[0028] In a third aspect, the present invention provides a recombinant cell. According to an embodiment of the present invention, the recombinant cell carries the nucleic acid molecule of the first aspect of the present invention or the expression vector of the second aspect of the present invention.
[0029] According to some specific embodiments of the present invention, the recombinant cells can efficiently and massively express nucleic acid molecules under appropriate conditions. The nucleic acid molecules have stronger recognition specificity for insulin or its analogs. Efficient detection can be achieved with a smaller sample volume, lower cost, higher detection accuracy and sensitivity, and a larger window value, which is of great significance for the industrial production of detection of insulin or its analogs.
[0030] According to an embodiment of the present invention, the recombinant cell may further include at least one of the following additional technical features:
[0031] According to an embodiment of the present invention, the recombinant cell is selected from at least one of CRFK, HEK293FT, HEK293T, HEK293 or BHK cells.
[0032] According to an embodiment of the present invention, the recombinant cell is a HEK293 cell.
[0033] In a fourth aspect, the present invention provides a method for detecting the biological activity of insulin or its analogs. According to an embodiment of the present invention, the method comprises: contacting a sample of insulin or its analogs to be tested with the recombinant cell described in the third aspect of the present invention; detecting a luminescent signal from the contact product, and calculating the biological activity of the insulin or its analog based on the luminescent signal.
[0034] According to a specific embodiment of the present invention, the method for detecting insulin or its analogs developed by the inventors has the advantages of a larger detection window value, higher accuracy, better precision, smaller variation, simpler operation, and lower detection cost.
[0035] According to an embodiment of the present invention, the above detection method may further include at least one of the following additional technical features:
[0036] According to an embodiment of the present invention, after the contact treatment and before the detection treatment, an incubation treatment is further included, wherein the contact treatment product is incubated in a 37°C, 5% CO2 incubator for a certain period of time, preferably, incubated for 10 to 20 hours, more preferably, incubated for 15 hours.
[0037] It should be noted that, depending on the reporter gene selected, after incubation, a luciferase substrate must be added to the incubation product before fluorescence signal detection can be performed. If the reporter gene selected can directly perform fluorescence excitation, there is no need to add a luciferase substrate. The aforementioned luciferase substrate can be generally selected according to the experiment.
[0038] According to an embodiment of the present invention, the volume of the sample to be tested is 18-24 μl, preferably 20 μl.
[0039] In a fifth aspect, the present invention provides a kit. According to embodiments of the present invention, the kit comprises: the nucleic acid molecule described in the first aspect of the present invention, the expression vector described in the second aspect of the present invention, or the recombinant cell described in the third aspect of the present invention. The kit of the present invention can rapidly and accurately detect insulin or its analogs at a lower cost and is widely applicable to scientific research and clinical medical applications.
[0040] According to an embodiment of the present invention, the above-mentioned kit may further include at least one of the following additional technical features:
[0041] According to an embodiment of the present invention, the kit further includes an activity curve or instructions of a standard substance of insulin or its analogs.
[0042] In a sixth aspect of the present invention, the present invention provides a use of the nucleic acid molecule described in the first aspect of the present invention, the expression vector described in the second aspect of the present invention, the recombinant cell described in the third aspect of the present invention, or the kit described in the fourth aspect of the present invention for detecting the biological activity of insulin or its analogs. According to embodiments of the present invention, the kit for detecting the activity of insulin or its analogs has advantages such as a larger detection window, high accuracy, ease of use, and good cost-effectiveness.
[0043] Additional aspects and advantages of the present invention will be set forth in part in the description which follows and, in part, will be obvious from the description which follows, or may be learned by practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] The above and / or additional aspects and advantages of the present invention will become apparent and readily understood from the description of the embodiments with reference to the following drawings, in which:
[0045] FIG1 is a map of a Luciferase reporter gene plasmid containing a CRE response element according to Example 1 of the present invention;
[0046] FIG2 is a performance evaluation result of cell lines corresponding to different STAT5b response element sequences according to Example 1 of the present invention;
[0047] FIG3 shows the functional evaluation results of the cell lines screened for monoclonal differentiation according to Example 1 of the present invention;
[0048] FIG4 is a result of specificity verification of the luciferase reporter gene detection method according to Example 2 of the present invention;
[0049] FIG5 is a linearity verification result of the luciferase reporter gene detection method according to Example 2 of the present invention;
[0050] FIG6 is a specificity verification result of the HTRF kit detection method according to Example 3 of the present invention;
[0051] FIG7 is a linearity verification result of the HTRF kit detection method according to Example 3 of the present invention;
[0052] FIG8 is a result of detecting the activity of ultra-long-acting insulin using the luciferase reporter gene detection method according to Example 4 of the present invention;
[0053] FIG9 is the activity detection results of different insulin preparations using the luciferase reporter gene detection method according to Example 4 of the present invention;
[0054] FIG10 is a luciferase reporter gene detection method according to Example 4 of the present invention for the activity detection results of Degludec compound preparation;
[0055] FIG11 is a result of detecting the activity of insulin glargine injection (Sanofi) using the luciferase reporter gene detection method according to Example 4 of the present invention;
[0056] FIG12 is a result of detecting the activity of insulin glargine injection (HEC) according to the luciferase reporter gene detection method of Example 4 of the present invention. DETAILED DESCRIPTION
[0057] The embodiments of the present invention are described in detail below, and examples of the embodiments are shown in the accompanying drawings. The embodiments described below with reference to the accompanying drawings are exemplary and intended to be used to explain the present invention, but should not be understood as limiting the present invention.
[0058] Definition and Explanation
[0059] Furthermore, the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of the technical features being referred to. Thus, a feature defined as "first" or "second" may explicitly or implicitly include at least one such feature. In the description of the present invention, "plurality" means at least two, such as two, three, etc., unless otherwise specifically defined.
[0060] The endpoints of the ranges and any values disclosed herein are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoints of each range, the endpoints of each range and individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered to be specifically disclosed herein.
[0061] Throughout this article, unless otherwise specified, "IR" stands for insulin receptor, a transmembrane glycoprotein with tyrosine kinase activity. The insulin receptor IR is divided into two subtypes: IRA and IRB. IRB is the primary receptor for insulin-induced blood glucose regulation. Insulin-stimulated cell lines bearing insulin receptors can indirectly reflect the biological activity of insulin by measuring the tyrosine kinase activity of IRB receptors.
[0062] Isolated nucleic acid molecules
[0063] In one aspect, the present invention provides an isolated nucleic acid molecule. According to an embodiment of the present invention, the nucleic acid molecule comprises sequences for expressing an insulin receptor B, a STAT5b response element, and a reporter gene. The insulin receptor B, STAT5b response element, and reporter gene sequences are linked.
[0064] expression vector
[0065] In another aspect of the present invention, the present invention provides an expression vector. According to an embodiment of the present invention, the expression vector carries the aforementioned isolated nucleic acid molecule.
[0066] recombinant cells
[0067] In another aspect of the present invention, an expression vector is provided. According to an embodiment of the present invention, the recombinant cell carries the aforementioned nucleic acid molecule or expression vector.
[0068] Method for detecting the activity of insulin or its analogs
[0069] In one aspect, the present invention provides a method for detecting the activity of insulin or an analog thereof. According to an embodiment of the present invention, the method comprises contacting an insulin sample with the aforementioned recombinant cell; performing a luminescence signal detection process on the contact product, and determining the activity of the insulin or an analog thereof based on the luminescence signal.
[0070] Specifically, for ease of understanding, the technical solution of this application is explained and illustrated in detail below:
[0071] 1) Preparation of reference and test solution
[0072] ① 0.6mM insulin glargine reference solution: Weigh an appropriate amount of insulin glargine reference solution, add 0.01M HCl to dissolve completely and dilute to 0.6mM, then mix well;
[0073] It should be noted that the reference solution can be selected from a commercially available standard solution or a solution prepared by oneself based on a pure reagent.
[0074] ②0.6mM insulin glargine test solution: take an appropriate amount of insulin glargine injection;
[0075] ③15000nM reference substance / test substance stock solution: Take 780μl of 0.01M hydrochloric acid solution, add 20μl of 0.6mM insulin glargine reference substance / test substance solution, and mix well.
[0076] ④ 1000 nM control substance / test substance solution: Take 780 μl of DMEM culture medium containing 1% FBS (fetal bovine serum) and add 20 μl of 15000 nM control substance / test substance stock solution.
[0077] ⑤ Gradual dilution of control / test compound: in a 96-well plate, dilute according to the method shown in Table 1;
[0078] Table 1:
[0079] Note: R represents the control group; T represents the test group.
[0080] 2) Preparation of cell suspension
[0081] Remove the culture flask from the incubator, discard the culture medium, add 2ml DPBS (sterile saline) buffer and wash gently twice. Slowly add 1ml DPBS and 1ml trypsin solution along the wall (cell-free side) to digest the cells for about 2 minutes. When the cytoplasm shrinks, the intercellular space increases, or a few cells fall off, gently shake to make all the cells fall off, add 3ml of complete culture medium to the culture flask, and gently blow to disperse the cells. Use a pipette to transfer the cell suspension to a centrifuge tube, centrifuge at 900rpm for 5min, pour out the supernatant, add 1ml of DMEM culture medium containing 1% FBS to resuspend, and use a pipette to gently blow to make the cells into a single suspension, take out 10μl from it and put it into a 0.2ml centrifuge tube, add 10μl of trypan blue solution to the tube, blow evenly, take out 10μl from the mixed solution onto a cell counting plate, and calculate the density of living cells.
[0082] The cell suspension density was adjusted to 500,000 cells / ml using DMEM medium containing 1% FBS, and 20 μl was added to each well of a 384-deep-well plate using a 12-channel dispensable pipette, so that the number of cells was 10,000 cells / well.
[0083] 3) Co-incubation
[0084] Pipette 2× test sample serial dilutions into the corresponding wells along the wall, 20 μl per well, and replicate three wells for each concentration point.
[0085] After the above solutions were added, the 384-well plate was covered with a transparent sealing film and placed in a 37° C., 5% CO 2 incubator for incubation for 15 h.
[0086] 4) Fluorescence signal detection
[0087] After incubation for 15 hours, the 384-deep-well plate was taken out of the incubator and placed at room temperature for about 5 minutes. Then, 30 μl of luciferase substrate was quickly added to each well along the wall using a pipette. After 3 minutes, the luminescence signal was detected in the LUM mode in a multifunctional microplate reader.
[0088] 5) Calculation
[0089] With log (actual concentration of compound) as the abscissa and bioluminescence value as the ordinate, GraphPad Prism software was used for four-parameter fitting. The specific formula is as follows:
[0090] in:
[0091] Y is the bioluminescence value of each well;
[0092] X is the log(compound concentration) value, nmol / L;
[0093] A is the asymptote estimate under the curve (i.e., bottom value);
[0094] D is the asymptote estimate on the curve (i.e., top value);
[0095] B is the slope of the curve (i.e. HillSlope value);
[0096] EC 50 is the half-maximal effect concentration, nmol / L.
[0097] The relative biological activity of the test solution was calculated according to the following formula:
[0098] A=(EC 50R / EC 50S )×100%
[0099] in:
[0100] A is the relative biological activity of the test sample, %;
[0101] EC 50R The half-maximal effect concentration of the reference solution is calculated from the curve, nmol / L;
[0102] EC 50S The half-maximal effect concentration of the test solution is calculated from the curve, nmol / L.
[0103] The following examples are described in detail. Where specific techniques or conditions are not specified in the examples, the experiments were performed according to those described in the literature in the art or according to the product instructions. Reagents or instruments used, for which the manufacturer is not specified, are commercially available conventional products.
[0104] It should be noted that, in the present application, the method for detecting the activity of insulin or its analogs has the same meaning as the method for detecting the luciferase reporter gene.
[0105] Example 1: Construction of a luciferase reporter gene cell line
[0106] 1.1 Construction of reporter gene plasmid
[0107] The present invention constructed three STAB5b response elements, having the nucleic acid sequences shown in SEQ ID NOs: 1 to 3. The CRE response element in the Luciferase reporter gene plasmid (Figure 1) was replaced with a STAB5b response element (Guangzhou Aiki Biotechnology Co., Ltd.), resulting in three Luciferase reporter gene plasmids containing the STAT5b response element (labeled STAB5b-01-Luciferase, STAB5b-02-Luciferase, and STAB5b-03-Luciferase, respectively, according to SEQ ID NOs: 1 to 3).
[0108] 1.2 Cell line construction
[0109] 1.2.1 The HEK293-IRB monoclonal cell line that had been transformed into insulin receptor IRB was taken out of the liquid nitrogen tank and cultured at 37°C, 5% CO2 (the following culture conditions are all 37°C, 5% CO2) in DMEM complete medium containing 10.0% FBS and 1% double antibiotic (penicillin / streptomycin) for 3 days for recovery. 6 Cells / well were seeded into 6-well plates and placed in an incubator for about 48 hours before use;
[0110] 1.2.2 The punctured bacteria containing the three reporter gene plasmids of STAT5b-01-Luciferase, STAT5b-02-Luciferase, and STAT5b-03-Luciferase were inoculated into LB liquid medium (containing 100 μg / mL ampicillin) and cultured with shaking at 250 rpm and 37°C overnight. The plasmids were extracted using a plasmid extraction kit (Thermo). The constructed recombinant plasmids were linearized with Pvu I endonuclease, and the linearized products were recovered. The linearized recombinant expression plasmids were stably transfected into HEK293-IRB cells using lipofectamine LP3000 transfection. Three stable cell lines, HEK293 / IRB-STAT5b-01-Luciferase, HEK293 / IRB-STAT5b-02-Luciferase, and HEK293 / IRB-STAT5b-03-Luciferase, were obtained by hygromycin B (final concentration 300 μg / ml) pressure selection. After luciferase assay, two mixed cell lines, HEK293 / IRB-STAT5b-02-Luciferase and HEK293 / IRB-STAT5b-03-Luciferase, were selected for subsequent cloning screening.
[0111] 1.2.3 The two mixed cell lines after pressure screening and passage were plated in 96-well plates for limiting dilution monoclonal screening at 0.30 cells / well. The 96-well plates were cultured for 15 days. Microscopic examination was performed to screen the wells containing single cell clusters in the 96-well plates. 48 cell clones were selected and passaged to 24-well plates for 5 days. 35 cell clones with normal growth in the 24-well plates were selected by microscopic examination and passaged at a ratio of 1:2. Each cell clone was passaged to two wells, with cells from one well used for passage and cells from the other well used for analysis and testing of the screening results. The 24-well plate cells were cultured in a CO2 incubator for 6 days. Based on the analysis and test results, 6 cell clones were selected for expansion and passage to T25 culture flasks, labeled as: 001#clone, 002#clone, 003#clone, 004#clone, 005#clone, and 006#clone. Cells were cultured in T25 flasks in a CO2 incubator for three days and then passaged at a 1:2 ratio. Each cell clone was passaged twice across two T25 flasks, with one flask used for passage and the other for further analysis and screening. Based on the activity assay results, clone 001# was ultimately selected as the optimal clone. Clone 001# was derived from a mixed HEK293 / IRB-STAT5b-03-Luciferase cell line.
[0112] 1.3 Functional evaluation of cell lines
[0113] The results, shown in Figure 2, show that the cell lines corresponding to STAT5b-02-Luciferase and STAT5b-03-Luciferase exhibited a higher response to insulin stimulation and a wide detection window (with a signal-to-noise ratio exceeding 90-fold), meeting the requirements for bioactivity analysis. The STAT5b-03 sequence element exhibited a greater response and was selected as the preferred element for further cloning to verify the effectiveness of the cell construct.
[0114] 1.3.1 Functional evaluation of cell lines screened for monoclonal selection
[0115] As shown in Figure 3, the HEK293 / IRB-STAT5b-03-Luciferase #001 clone showed the most sensitive response to insulin stimulation, with the largest detection window (signal-to-noise ratio exceeding 100-fold). The optimal cell line, clone #001, was identified, and its corresponding STAT5b-03 sequence element was the most preferred, enabling further analytical method development.
[0116] Example 2: Luciferase reporter gene method validation
[0117] 2.1 Specificity Verification
[0118] As shown in Figure 4, there was no obvious dose-effect relationship after stimulation of cells by the liraglutide (non-target drug) group and the blank solvent group of insulin glargine injection (pure solvent without the addition of insulin glargine API). However, there was an obvious dose-effect relationship (the relationship between the input amount and the effect) after stimulation of cells by the reference standard group of insulin glargine injection and the high-temperature destruction solution group of insulin glargine. The linear relationship was good, and R 2 All were greater than 0.98, and the EC of the high temperature destruction solution group 50 The value (58.48nM) was significantly greater than the EC 50 In other words, this method can sensitively detect a certain decrease in the biological activity of the insulin glargine injection after high-temperature destruction. In summary, this analytical method has excellent specificity.
[0119] 2.2 Precision (Repeatability and Intermediate Precision) Verification
[0120] Different analysts tested the same batch of test samples (prepared in 6 portions in parallel) and reference materials using the above-mentioned assay method on different dates. The statistical results are shown in Tables 2 to 4:
[0121] Table 2:
[0122] Table 3:
[0123] Table 4:
[0124] Through analysis, it can be seen that different analysts used this method to conduct parallel tests on 6 test samples on different days. The individual GCV values were 1.24% and 4.84% respectively. The GCV value of 12 samples was 3.48%, indicating that this analytical methodology has good repeatability, small variability and high precision.
[0125] 2.3 Linearity and Accuracy Verification
[0126] Two different analysts prepared linear solutions (also known as accuracy solutions) of insulin glargine at potency levels of 50%, 75%, 100%, 125%, and 150% on different days and tested them according to the above assay method. The statistical results are shown in the following table:
[0127] Table 5:
[0128] Table 6:
[0129] From the combined analysis of Table 5, Table 6 and Figure 5, it can be seen that this analysis method has a good linear relationship within the detection range of 50% to 150% (R 2=0.9959), with high accuracy (the recovery rates of the accuracy solutions at each titer level were between 88% and 107%).
[0130] Example 3: Comparison of different detection methods
[0131] According to the embodiments of the present invention, the method for detecting insulin or its analogs according to the present invention is shown to have higher superiority by comparing its performance and cost with commercially available kits.
[0132] 3.1 Cost Comparison
[0133] By comparing the market price with the cost of the method of the present invention (Table 7), the luciferase reporter gene analysis method for detecting the biological activity of insulin glargine injection developed by the present invention has obvious cost advantages over the technical means of commercial kits such as HTRF and AlphaElisa.
[0134] Table 7:
[0135] 3.2 Specificity comparison
[0136] The specificity of the HTRF kit assay was similar to that of the reporter gene assay described above. It showed no response to non-target drugs (specific solution group, i.e., liraglutide), blank solvents, hydrochloric acid solutions, and was able to detect the decrease in biological activity of drugs destroyed by high temperature (Figure 6).
[0137] 3.3 Precision comparison (repeatability and intermediate precision)
[0138] Two different analysts used the same batch of test products (prepared in 6 parallel portions) and reference products to perform tests using the HTRF kit assay method on different dates. The statistical results are shown in Tables 8 to 10.
[0139] Table 8:
[0140] Table 9:
[0141] Table 10:
[0142] From the above analysis, it can be seen that when the HTRF kit method is used to detect glargine insulin injection, the precision GCV is greater, indicating that compared with the reporter gene analysis method of the present invention, the HTRF kit method has greater variability.
[0143] 3.4 Comparison of Linearity and Accuracy
[0144] Two different analysts prepared linear solutions (also known as accuracy solutions) of insulin glargine at potency levels of 50%, 75%, 100%, 125%, and 150% on different days and tested them using the HTRF kit assay. The statistical results are shown in Table 11. The spike recovery rate using the HTRF kit assay fluctuated more significantly. Statistical analysis revealed that the luciferase reporter gene assay developed by the present invention for detecting the biological activity of insulin glargine injection was close to the theoretical value (correlation 0.981, Figure 7).
[0145] Table 11:
[0146] Example 4: Application of biological activity detection of insulin or its analogs
[0147] 4.1 Ultra-long-acting insulin testing
[0148] According to an embodiment of the present invention, a gradient dilution of a compound of ultra-long-acting insulin with a dosage range of 115.6 nM to 10000 nM was used to treat ultra-long-acting insulin (A14E, B16H, B25H, B29K (N (ε) -COOH (CH2)) using the method of the present invention (see the detailed embodiment section for details). 16 CO-L-Lys-CO(CH2)2CO-(OEG)2),desB30 human insulin analog) were used for activity detection.
[0149] The results are shown in Figure 8. The detection method of the present invention was used to detect ultra-long-acting insulin. It was found that the reporter gene bioactivity analysis method has good applicability to it (ultra-long-acting insulin), good dose-effect relationship, and high repeatability, and can be used for in vitro bioactivity detection and research of ultra-long-acting insulin.
[0150] The results are shown in Figure 9. The detection method of the present invention was used to conduct in vitro efficacy studies on HEC's self-developed ultra-long-acting insulin molecules. By comparing the biological activities of recombinant human insulin, icodec, and degludec insulin after IRB phosphorylation, it was verified that the in vitro efficacy of HEC's self-developed ultra-long-acting insulin molecules met the design purpose. The results of this method showed that the biological activity of HEC's self-developed ultra-long-acting insulin molecules after IRB phosphorylation was equivalent to that of icodec, significantly lower than that of degludec insulin, and even more significantly lower than that of recombinant human insulin after IRB phosphorylation, which is consistent with the theoretical value, indicating that the present invention can accurately reflect the in vitro biological activity of insulin analog molecules with different design purposes, and can be used for in vitro mechanism studies of insulin analogs and screening of new insulin analog molecules.
[0151] 4.2 Degludec and Aspartame Combination
[0152] According to an embodiment of the present invention, a gradient dilution of the compound of the degludec and aspartate combination preparation with a dilution factor ranging from 1 to 256 was used to test the activity of the degludec and aspartate combination preparation using the method of the present invention (see the detailed embodiment section for details).
[0153] The results are shown in Figure 10. The detection method of the present invention was used to detect the degludec and aspartate compound preparation. It was found that the reporter gene bioactivity analysis method has good applicability to it (degludec and aspartate compound preparation), good dose-effect relationship, and high repeatability, and can be used for in vitro bioactivity detection and research of degludec and aspartate compound preparation.
[0154] 4.3 Activity Assay for Insulin Glargine Injection (Sanofi)
[0155] According to an embodiment of the present invention, the method for detecting insulin or its analogs of the present invention was used to detect the activity of insulin glargine injection produced by Sanofi. The specific steps are detailed in the specific embodiment (insulin or its analog activity detection method section).
[0156] The results showed that the relative biological activity of insulin glargine injection (Sanofi) detected by the method of the present invention was 105% ( FIG. 11 ).
[0157] 4.4 Activity Assay for Insulin Glargine Injection (HEC)
[0158] According to an embodiment of the present invention, the method for detecting insulin or its analogs of the present invention was used to detect the activity of insulin glargine injection produced by HEC. The specific steps are detailed in the specific embodiment (insulin or its analog activity detection method section).
[0159] The results showed that the relative biological activity of insulin glargine injection (HEC) detected by the method of the present invention was 105% ( FIG. 12 ).
[0160] In summary, as shown in the above examples, the method for detecting the activity of insulin or its analogs designed by the present invention can be widely used.
[0161] In the description of this specification, the reference terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" mean that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art can combine and combine different embodiments or examples described in this specification and features of different embodiments or examples without contradiction.
[0162] Although the embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention.
Claims
1. An isolated nucleic acid molecule, It is characterized in that include: A first nucleic acid segment, wherein the first nucleic acid segment encodes insulin receptor B; a second nucleic acid segment encoding a STAT5b response element; a third nucleic acid fragment, wherein the third nucleic acid fragment encodes a reporter gene; The STAT5b response element comprises a nucleic acid sequence as shown in any one of SEQ ID NOs: 1 to 3; The first nucleic acid fragment, the second nucleic acid fragment and the second nucleic acid fragment are connected or not connected to the third nucleic acid fragment.
2. The nucleic acid molecule according to claim 1, It is characterized in that The second nucleic acid fragment is linked to the third nucleic acid fragment.
3. The nucleic acid molecule according to claim 1, It is characterized in that The STAT5b response element comprises the nucleic acid sequence shown in SEQ ID NO:
3.
4. The nucleic acid molecule according to claim 1, It is characterized in that The reporter gene includes at least one of Lucifererase gene, CAT gene, YFP gene or GFP gene; Preferably, the reporter gene is a Lucifererase gene.
5. The nucleic acid molecule according to claim 1, It is characterized in that The insulin receptor protein B comprises the amino acid sequence shown in SEQ ID NO:4; Optionally, the reporter gene comprises the amino acid sequence shown in SEQ ID NO:
5.
6. The nucleic acid molecule according to claim 1, It is characterized in that The first nucleic acid fragment comprises the nucleotide sequence shown in SEQ ID NO:6; Optionally, the third nucleic acid fragment comprises the nucleotide sequence shown in SEQ ID NO:
7.
7. An expression vector, It is characterized in that Carrying any nucleic acid fragment according to claim 1 or a nucleic acid molecule according to any one of claims 1 to 6.
8. The expression vector according to claim 7, It is characterized in that The expression vector is a non-pathogenic viral vector; Optionally, the non-pathogenic virus is selected from at least one of a retrovirus, a lentivirus and an adenovirus-associated virus.
9. A recombinant cell, It is characterized in that Carrying the nucleic acid molecule according to any one of claims 1 to 6 or the expression vector according to any one of claims 7 to 8; Optionally, the recombinant cell is selected from at least one of CRFK, HEK293FT, HEK293T, HEK293 or BHK cells; Preferably, the recombinant cell is a HEK293 cell.
10. A method for detecting the biological activity of insulin or its analogs, It is characterized in that include: contacting a sample of insulin or its analogs to be tested with the recombinant cell according to claim 9; The contact treatment product is subjected to luminescence signal detection processing, and the biological activity of insulin or its analogue is calculated based on the luminescence signal.
11. The method according to claim 10, It is characterized in that After the contact treatment, the incubation treatment is further included before the detection treatment. The incubation treatment is to incubate the contact treatment product at 37°C and 5% CO 2 Incubate in an incubator for 10 to 20 hours, preferably, incubate for 15 hours; Optionally, the volume of the sample to be tested is 18-24 μl, preferably 20 μl.
12. A kit, It is characterized in that The kit comprises: the nucleic acid molecule according to any one of claims 1 to 6, the expression vector according to any one of claims 7 to 8, or the recombinant cell according to claim 9.
13. The kit according to claim 12, It is characterized in that The kit further includes an activity curve or instructions of a standard substance of insulin or its analogs.
14. Use of the nucleic acid molecule according to any one of claims 1 to 6, the expression vector according to any one of claims 7 to 8, the recombinant cell according to claim 9 or the kit according to any one of claims 12 to 13 in detecting the biological activity of insulin or its analogs.
15. The nucleic acid molecule according to any one of claims 1 to 6, the expression vector according to any one of claims 7 to 8, the recombinant cell according to claim 9 or the kit according to any one of claims 12 to 13 is used for detecting the biological activity of insulin or its analogs.
Citation Information
Patent Citations
Method and kit for detecting biological activity of insulin or analogue thereof
CN116751817A
Cell model for sifting anti-diabetic drugs
CN101200707A
Efficient sgRNA screening system and efficient sgRNA screening method
CN106636154A
Codon optimized precursor gene and signal peptide gene of human insulin analogue
CN111094572A
Human-derived single-chain insulin analogue and application thereof
CN114591417A
